Elizabeth Bhatt
Directeur des opérations chez Septerna, Inc.
Fortune : 578 $ au 31/05/2024
Postes actifs de Elizabeth Bhatt
Sociétés | Poste | Début | Fin |
---|---|---|---|
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Directeur des opérations | 01/06/2022 | - |
Historique de carrière de Elizabeth Bhatt
Anciens postes connus de Elizabeth Bhatt
Sociétés | Poste | Début | Fin |
---|---|---|---|
EFFECTOR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 25/08/2021 | 21/06/2024 |
Independent Dir/Board Member | 25/08/2021 | 21/06/2024 | |
APPLIED MOLECULAR TRANSPORT INC. | Corporate Officer/Principal | 01/09/2019 | 31/05/2022 |
ACHAOGEN | Directeur des opérations | 26/07/2018 | 30/06/2019 |
Corporate Officer/Principal | 18/09/2017 | 26/07/2018 | |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/05/2011 | 01/09/2017 |
EFFECTOR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2021 | - |
Independent Dir/Board Member | 01/01/2021 | - |
Formation de Elizabeth Bhatt
Pomona College | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
University of California San Diego | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Elizabeth Bhatt
- Expérience